How HER2 affects brown fat in breast cancer patients
Part of Cancer, Skin clinical trials.
This study looks at how a protein called HER2 affects brown fat activity in women with breast cancer. Brown fat helps burn calories and may influence treatment outcomes. You will be assigned to one of two groups based on your cancer's HER2 status, and the study will measure how your brown fat responds to cold.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman over 18 years old.
- You have been diagnosed with breast cancer that is estrogen receptor positive (ER+).
- The cancer has not spread to other parts of the body (non-metastatic).
- You have not had chemotherapy or other treatments before surgery (no prior neoadjuvant treatment).
- Your body's brown fat responds to cold (shown by a temperature change of more than 1°C after cooling).
- You are scheduled to receive chemotherapy after surgery (adjuvant chemotherapy) along with hormone therapy (and possibly HER2-targeted therapy, depending on your HER2 status).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study looks at different treatment plans after surgery for people with HER2-positive breast cancer who still have cancer cells remaining after initial chemo and trastuzumab. It aims to see which approach helps improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.